Sanofi will host an online science session to present results of a Phase 2b clinical trial testing the safety and efficacy of its investigational, oral BTK inhibitor SAR442168 in people with multiple sclerosis (MS).
The virtual session, owing to the cancellation of the American Academy of Neurology (AAN)’s 2020 annual meeting due to the COVID-19 pandemic, is set for Thursday, April 23, from 8:00-9:00 am EST. Registration can be found here.
SAR442168 is designed to block the activity of a protein called Bruton’s tyrosine kinase (BTK). This protein is important for the inflammation-driving activity of certain types of immune cells, most notably B-cells. By blocking BTK, SAR442168 is expected to lessen the inflammation that causes nervous system damage in MS.
The investigational therapeutic is being developed by Sanofi, in collaboration with Principia Biopharma.
“During these unprecedented times we remain committed to sharing results that allow us to advance the understanding of multiple sclerosis and the impact our potential brain-penetrant BTK inhibitor could have on the lives of people living with this disease,” John C. Reed, MD, PhD, the global head of research and development at Sanofi, said in a press release.
“Our virtual session will provide the opportunity for an important scientific exchange and a forum for sharing the recent clinical results obtained with our brain-penetrant BTK inhibitor for multiple sclerosis,” Reed added.
Results of a Phase 1 trial (ACTRN12617001457336) conducted in healthy volunteers showed SAR442168 (previously known as PRN2246) to have a good safety profile, with no serious treatment-related adverse events reported.
Findings also showed that the therapy was present in the fluid around the brain and spinal cord in dosed individuals. This is important, as it shows that SAR442168 can cross the blood-brain barrier — a barrier that prevents harmful substances in the blood from entering the brain. Getting past this barrier and into the brain is critical for therapies designed to affect the nervous system.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?